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Abstract
Background
The potential effect of ginger on platelet aggregation is a widely-cited concern both within
the published literature and to clinicians; however, there has been no systematic appraisal
of the evidence to date.
Methods
Using the PRISMA guidelines, we systematically reviewed the results of clinical and obser-
vational trials regarding the effect of ginger on platelet aggregation in adults compared to
either placebo or baseline data. Studies included in this review stipulated the independent
variable was a ginger preparation or isolated ginger compound, and used measures of
platelet aggregation as the primary outcome.
Results
Ten studies were included, comprising eight clinical trials and two observational studies. Of
the eight clinical trials, four reported that ginger reduced platelet aggregation, while the
remaining four reported no effect. The two observational studies also reported mixed
findings.
Discussion
Many of the studies appraised for this review had moderate risks of bias. Methodology var-
ied considerably between studies, notably the timeframe studied, dose of ginger used, and
the characteristics of subjects recruited (e.g. healthy vs. patients with chronic diseases).
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Conclusion
The evidence that ginger affects platelet aggregation and coagulation is equivocal and fur-
ther study is needed to definitively address this question.
Introduction
There is increasing evidence that ginger and its constituents might exert meaningful anti-nau-
sea effects during cancer chemotherapy. Our recent systematic review of the literature found
preliminary evidence that supported its use as an adjuvant anti-nausea drug to standard anti-
emetics in the chemotherapy setting.[1] Concerns over potential “off target” antiplatelet effects,
however, could limit the application of ginger in oncology patients, who frequently experience
thrombocytopenia due to myelosuppression.
The ginger rhizome has been used in traditional systems of medicine for centuries and more
recently, its potentially medicinal properties have been empirically studied.[2] Current research
suggests that the active constituents of ginger, namely the gingerol and shogaol classes of com-
pounds, might exert several beneficial effects including anti-inflammatory, antioxidant, and
cholesterol lowering properties.[2] In addition, ginger is a promising treatment for nausea
associated with a variety of stimuli including post-operative nausea and vomiting, motion sick-
ness, morning sickness, and chemotherapy-induced nausea and vomiting.[1, 3–5]
While the safety profile of ginger supplementation requires further investigation, previous
clinical trials report few side-effects, mostly minor in nature (e.g. mild nausea, heartburn).[1]
Of these reported side effects, potentially the most significant is an antiplatelet effect. Two pub-
lished case-studies reported adverse symptoms and abnormal platelet aggregation that was
temporally related to recent ingestion of ginger products.[6, 7] In addition, several animal and
in vitro studies have reported ginger as well as individual ginger compounds to have an effect
on platelet aggregation.[8–10] While this action could be beneficial in vascular diseases, it
could potentiate bleeding risk in conditions such as thrombocytopenia or pre-existing platelet
dysfunction. This is particularly relevant in the chemotherapy setting, where therapy-induced
thrombocytopenia is associated with treatment delays, dose reductions, and bleeding events.
[11]
To the authors knowledge, Srivastava et al.[8] were the first group to investigate the effect of
ginger on platelet aggregation by using four ginger extracts, produced using different solvents
(aqueous, n-hexane, chloroform, and ethyl acetate). They reported that ginger inhibited platelet
aggregation using arachidonic acid (AA), epinephrine, adenosine diphosphate (ADP), and col-
lagen as agonists. Others have corroborated this, reporting that certain ginger compounds
inhibit in vitro platelet aggregation when using a variety of agonists (AA, collagen, platelet acti-
vating factor, and thrombin).[12, 13] This reduction in platelet aggregation was most potent
when AA was used as the agonist, requiring lower concentrations to cause inhibition when
compared to the other agonists.[9, 12]
While few studies investigating the effect of ginger and its compounds on the clotting cas-
cade have been undertaken, a considerable amount of in vitro research suggests that ginger
compounds interact with AA-derived eicosanoid and thromboxane synthesis.[14–18] The AA
cascade can produce the eicosanoids involved in inflammation (i.e. prostaglandin E2) as well as
thromboxane, which is amongst the many agonists of platelet aggregation. Numerous studies
indicate that ginger extract and particular ginger compounds inhibit products specific to the
cyclooxygenase pathway, including a reduction in thromboxane B2 (TxB2) production,[19]
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prostaglandin formation (PGF2a, PGE2, and PGD2),[8, 15] and cyclooxygenase enzyme activ-
ity.[16, 18] These same compounds also interact with the lipoxygenase pathway, including
reductions in 5-lipoxygenase enzyme activity.[14] Finally, ginger compounds might also
inhibit the activity of phospholipase A2, which suggests that ginger exerts its anti-platelet aggre-
gating as well as its potential anti-inflammatory actions through interaction with one of the ini-
tial steps in this pathway.[20]
Due to the observed in vitro effects of ginger on the AA cascade, excessive bleeding and
interactions with platelet therapy during cancer chemotherapy are of clinical concern. While
the results of in vitro studies are consistent, these results are not always translatable to the com-
plex human system. Clinical and observational data, however, provide a reasonable indication
of the potential human response. There is a growing body of clinical and epidemiological litera-
ture in this area, although no systematic appraisal of the relevant literature has been under-
taken to date. In this paper, we summarise and discuss the findings of clinical and
observational studies regarding the effect of ginger, compared to placebo or baseline, on plate-
let aggregation in multiple participant populations.
Methodology
2.1 Data Sources and Searches
Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines,[21] a systematic search of the literature was conducted using the following data-
bases: MEDLINE, CiNAHL, Embase, and Cochrane Library. The reference lists of retrieved
papers were also searched for additional manuscripts. Search terms were not limited by a spe-
cific timeframe; rather, all search queries were from the date of the journal’s inception to May
2014. Search terms were broad so as to ensure all relevant manuscripts were captured.
2.2 Study Selection
The search terms used were “ginger AND (platelet OR thrombo OR clot OR bleed OR
“adverse effects” OR “side effects” OR haemorrhage)”. Studies included in this review 1) were
written in English 2) stipulated the independent variable was a ginger preparation or isolated
ginger compound, and 3) used measures of platelet aggregation as the primary outcome.
2.3 Data Extraction and Quality Assessment
Extracted data included: participant demographic (e.g age, gender, reported comorbidities),
type of ginger intervention (e.g dosage, timing, form of ginger), study design characteristics
(e.g. sample size, risk of bias, type of study, study length), and reported outcomes (e.g measures
of platelet aggregation, adverse events, dropout rates).
All clinical studies were individually rated for evidence level by author WM using the
National Health and Medical Research Council Hierarchy of Evidence guidelines (IV-I, with I
being the strongest level of evidence).[22] They were also independently assessed for bias, by
two authors (WM and DM) using the Cochrane Handbook for Systematic Reviews of Interven-
tions checklist.[23] Where insufficient information was included in the manuscript to assess
particular forms of bias, further information was sought via correspondence with the study
authors. Blinding is unlikely to affect the results of the clinical biomarkers measured in these
studies, hence trials that were not blinded were rated in the review as low-risk for detection and
performance included bias. In addition, due to the small number of trials in this area, no study
was excluded based on its risk of bias.
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2.4 Data Synthesis and Analysis
A statistically significant (P0.05) result was considered evidence of an effect. Relevant study
details were retrieved from their respective manuscript using a standardised form. Forest plot
and meta-analysis was intended; however, due to the heterogeneity of the studies included in
this review, these analyses were found to be unfeasible.
Results
A total of 367 papers were identified (Fig 1). After assessment of study abstracts and the
removal of duplicates 26 abstracts were retrieved for further examination. Seventeen were sub-
sequently excluded, resulting in 9 manuscripts included in the final review.
3.1 Clinical Trials
Seven manuscripts reporting the effect of ginger on platelet aggregation in human partici-
pants using a clinical trial design were retrieved (Table 1). Of the seven manuscripts, one
Fig 1. PRISMA study flow diagram.
doi:10.1371/journal.pone.0141119.g001
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described two separate trials, resulting in a total of eight clinical trials included in this review.
[24]
The methodology varied considerably between trials. Half of the studies used a cross-over
design[25–28] while three used a parallel design[19, 24] and one was a single arm study.[19]
Most of the studies (7/8) had elements of robust study design such as placebo controls, rando-
misation and double-blinding. However, few studies incorporated all of these elements, with
only two studies featuring both randomisation and double-blinding procedures. For example,
Jiang et al.[26] used a randomised cross-over design that was also open-label (Table 1). Despite
this, the assessment of bias determined the majority of studies were relatively low-risk in terms
of performance, detection, and attrition bias while a high risk of random sequence generation
and allocation concealment bias was detected (Fig 2).
The average sample size was small. Seven of the eight studies ranged from 7–36 participants
[19, 25–29] with one study comprising 60 participants.[24] The duration of each study varied
considerably, ranging from one day to three months. Six of the eight studies included healthy
participants,[19, 25–27, 29] two studies included patients with confirmed myocardial infarc-
tion and one study included hypertensive patients as well as healthy participants.[24, 28] Most
studies required participants to consume only ginger, either as a supplement or as a food prep-
aration, while three studies measured the effect of ginger in combination with various medica-
tions and food products including nifedipine,[28] warfarin,[26] custard,[30] and a high-calorie
diet.[29]
In terms of the ginger preparation used, seven of the eight studies tested a dose of 3.6g to 5g,
while one cross-over study investigated larger doses of ginger with each participant receiving
either 10g or 40g per day.[30] Most studies delivered ginger at either one time point or once
per day, depending on the trial timeframe; however, Jiang et al.[26] and Verma et al.[29] deliv-
ered ginger thrice and twice per day, respectively. All studies used an unstandardized ginger
preparation, either dried, cooked or raw ginger, delivered in an unprocessed form, within cap-
sules, or mixed into a medium (i.e. custard).
Measures of platelet aggregation varied between studies. The majority (6/8) used light trans-
mittance aggregometry or impedance aggregometry,[24, 26–29] while two studies assessed
thromboxane B2 production.[19, 25] Three studies also recorded multiple additional outcomes
including INR,[26] fibrinogen and fibrinolytic activity,[24] bleeding time, thromboelastogra-
phy and platelet count.[27] Of the six that used aggregometry, there was a mix of agonists used
Fig 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as
percentages across all included studies.
doi:10.1371/journal.pone.0141119.g002
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with ADP (5/6) and epinephrine (4/6) being the most common. Three studies also used one or
more of the following agonists: collagen, AA, or ristocetin.[26–28]
The reported effect of ginger on platelet function were equivocal. Two studies reported inhi-
bition of platelet aggregation.[24, 29] The first study found that ginger significantly inhibited
platelet aggregation in healthy males after consumption of a high-calorie diet.[29] The second
study reported that ginger the co-administration of 1g of ginger with nifedipine resulted in an
inhibition of platelet aggregation in normo- and hypertensive subjects.[28] However, in this
study, when ginger was administered alone, there was no significant effect.
In contrast, two studies reported that 2–3.6g of ginger had no effect on measures of platelet
aggregation in health adults.[26, 27] Moreover, Jiang et al.[26] found that the co-administra-
tion of 3.6g of ginger with 25mg of warfarin had no effect on the international normalized ratio
(INR) or the pharmacokinetics and pharmacodynamics of warfarin in healthy male partici-
pants. Lumb et al.[27] also reported no significant effect on bleeding time, platelet count, and
thromboelastography in a similar population. Bordia et al.[24] reported that 4g/day of ginger
for three months did not affect platelet aggregation, fibrinogen, or fibrinolytic activity in
patients with coronary artery disease; however, when participants were given a bolus dose of
10g ginger, there was a significant inhibition of platelet aggregation in patients with coronary
artery disease.
The two studies that investigated the effect of ginger on thromboxane B2 generation in
healthy adults reported conflicting results. Srivastava et al.[19] reported that 5g of ginger over 7
days resulted in a 37% inhibition of thromboxane B2 production (p<0.01), while Janssen et al.
[25] found that 15g and 40g of raw and cooked ginger, respectively, had no effect when each
were consumed for two weeks (p = 0.616).
3.2 Observational Data
Two observational studies investigated the association of ginger use and platelet-related
adverse effects. Shalansky et al.[31] conducted a 16-week longitudinal study of 171 participants
prescribed warfarin. During this period, participants were asked to record bleeding events as
well as factors that the investigators hypothesised could influence INR and bleeding risk,
including a selection of complementary therapies. Of the 171 participants, 87 reported bleeding
events with excessive bruising (41%) and nosebleeds (15%) being the two most commonly-
reported events. The study reported a significant association between self-reported bleeding
events and ginger (OR 6.63, 95% CI 3.49–12.61), as well as cayenne (OR 8.0, 95% CI 3.57–
17.92), willow bark (OR 9.00, 95% CI 6.42–12.62), St. John’s wort (OR 4.70, 95% CI 1.49–
14.79), and coenzyme Q10 (OR 3.91, 95% CI 2.09–7.31). Upon further analysis, ginger (OR
3.20, 95% CI 2.42–4.24) and coenzyme Q10 (OR 3.69, 95% CI 1.88–7.24) were independently
associated with self-reported bleeding events in a fully adjusted multivariate model. No com-
plementary therapies were associated with a risk of abnormal INR.
In contrast, Leung et al.[32] surveyed 314 patients prescribed warfarin therapy, in which
they retrospectively assessed self-reported bleeding events and exposure to factors that could
influence bleeding risk and INR in the previous month. While only two patients reported using
ginger during this period, the study authors determined that ginger, along with all other
assessed complementary therapies, was not associated with bleeding risk or abnormal INR.
Discussion
Despite consistent in vitro data demonstrating that ginger compounds interact with several
steps involved in platelet aggregation, the results of human studies are inconsistent. It is diffi-
cult to draw conclusions from these studies as a whole, due to the limited number of studies
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and their heterogeneous methods. These inconsistencies include the dose, dosing regimen, and
formulation of ginger used, the timeframe studied, and the characteristics of subjects recruited
(e.g. healthy vs. patients with chronic diseases).
Of the eight clinical trials analysed for this review, three found ginger affected measures of
platelet aggregation[24, 28, 29] and one study found ginger reduced thromboxane B2 produc-
tion.[19] When the included studies were separated by patient medical background (e.g.
healthy, hypertensive), no consistent treatment effect could be elucidated. However, there are
several limitations that could limit the real-world applicability of these results.
First, Young et al.[28] reported that ginger had an effect only when it was combined with
nifedipine, but not when it was ingested by itself. While not fully elucidated, it is thought that
the anti-aggregation effect of nifedipine results from the inhibition of intracellular Ca2+, which
attenuates platelet hyperactivity. [33] Other anti-platelet medications are not reported to pos-
sess this mechanism of action and therefore, these results might only be applicable to this
combination.
Second, Verma et al.[29] found that ginger reduced a rise in platelet aggregation after a two
week high-calorie diet when compared to control (high calorie diet plus placebo). However, it
should be noted that this diet exceeded the participants’ normal dietary intake (approximately
1600kcal increase in dietary intake, according to USDA food data[34]), which might make
these results difficult to compare to patients who consume a eucaloric diet.
The third study reported a significant reduction in platelet aggregation when a bolus of 10g
ginger was administered to patients with a confirmed myocardial infarction.[24] However, the
same authors found a lower dose of 4g ginger had no effect in the same population when taken
daily over three months.
A primary limitation of the studies reviewed is the lack of quantification or standardisation of
bioactive compounds in the ginger preparations used. This could partly explain the inconsistent
results. Previous research indicates that the concentration of the principal compounds within
ginger, namely gingerol and shogaols, varies greatly depending on the storage and preparation of
ginger products.[35, 36] This variation could result in significant differences in bioactive com-
pounds between studies. For example, 6-shogaol is only present in appreciable amounts in dried
or heated ginger as it is a degradation product of 6-gingerol.[37] Hence, preparations that used
dried ginger are likely to have significantly different effects compared to raw ginger.
A final limitation relates to the clinical significance of ginger’s potential anti-platelet effect.
Several studies have reported that ginger is effective for nausea in multiple settings including
morning sickness, motion sickness and chemotherapy-induced nausea and vomiting (CINV).
[4, 5, 38] However, the majority of these studies used ginger doses that were considerably lower
than those used in the studies included in this review. For example, in two recent reviews of the
effect of ginger on morning sickness[5] and CINV[1], from a total of 19 studies, no study used
a dose above 2g with most studies using a dosage around 1g. In contrast, the majority of studies
in this review that found a significant effect on platelet aggregation used doses above 5g.[19, 24,
29] Young et al.[28] were the only exception in reporting 1g in combination with nifedipine to
have an effect on platelet aggregation; however, when 1g of ginger was administered alone,
there was no significant effect. Hence, further research in this area should investigate the effect
of lower doses of ginger on platelet aggregation in order to determine if the potential effect of
ginger on platelet aggregation is clinically relevant when used as an adjuvant anti-nausea treat-
ment during chemotherapy at doses shown to be effective in previous studies.
The two observational studies included in this review also reported conflicting results.[31, 32]
This could be due to the differences in their study designs. One study undertook a retrospective
analysis that could have resulted in recall bias,[32] while the other study undertook a prospective
approach.[31] In the retrospective study,[32] only two patients from a cohort of 314 participants
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reported consuming ginger, both of whom reported experiencing bleeding events. Due to the
limited sample of participants who consumed ginger, it is difficult to drawmeaningful conclu-
sions. Information regarding the dose of ginger consumed by participants was not reported in
either observational study, which might further account for the difference in results.
While there was only one clinical trial investigating the interaction between ginger and war-
farin, Jiang et al.[26] found no significant change to patient INR when ginger was administered
for seven days. This is partially corroborated by the results of a study of Wistar rats in which a
proprietary ginger formulation, in combination with warfarin, had no additive effect on whole
blood clotting time, prothrombin time or activated partial thromboplastin time.[10] This is a
particularly relevant finding, as ginger is routinely cited as potentially interacting with warfarin
therapy.[39, 40] While further studies are required to investigate interaction of ginger and
blood thinning medication, current evidence does not support an interaction.
The results of this review indicate that the role of ginger in platelet aggregation is unclear
and therefore, future clinical trials are needed to further investigate this area, particularly in at-
risk populations such as chemotherapy patients. However, until these trials are undertaken, the
effect of ginger on platelet aggregation cannot be confidently dismissed. Previous research has
indicated that patient use of dietary supplements is often not reported to treating physicians.
For example, a review of surveys that investigated the rate of non-disclosure of complementary
and alternative medicines in chemotherapy patients found that between 40–50% of patients
did not discuss these therapies with their physician.[41] Hence, where patients are at particular
risk of bleeding, clinicians should ascertain patient consumption of dietary supplements and
screen for any known potentiator of bleeding risk.
Conclusion
Due to the potential effects of ginger on platelet aggregation, ginger is a commonly-cited exam-
ple of an herbal supplement that should be avoided in patients with thrombocytopenia, platelet
function defects or coagulopathy, such as populations using ginger for its antiemetic effect in
cancer chemotherapy. While in vitro data, as well as some clinical studies and epidemiological
evidence suggest that ginger inhibits platelet aggregation, the evidence is equivocal with multi-
ple limitations, particularly within the clinical data, which prevents firm recommendations
being made. Limitations include the lack of standardisation of ginger preparations used, signifi-
cant variations in dosage and time frame studied, and the high level of bias in the study designs
used. Therefore, further research is needed to clearly define the safety, or otherwise, of ginger
in patient population at increased risk of bleeding.
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